Biotech & Medtech
Biotech & Medtech news — Monday 16 November 2026
45 stories from 5 sources, every one in English. Each links to its publisher.
-
STAT+: New Trump regulation promises to crush ‘fraudsters.’ All the savings come from Medicare Advantage
The Trump administration proposed new regulations Monday that top officials say would “prevent fraud, remove bad actors, and protect the Americans who rely on” Medicare, Medicaid, and the Affordable Care Act marketplaces. Trump’s health…
-
STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
The Food and Drug Administration on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever. The approval of Wilserdly, also known as…
-
STAT+: Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs
A proposal by the Trump administration to cap the amount of time foreign students and scholars can spend in the country has been struck down in court. In a Monday ruling , Boston federal Judge F. Dennis Saylor IV wrote that the rule “is…
-
J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding
Johnson & Johnson’s Ollin Biosciences acquisition comes with a Phase 3-ready bispecific antibody. The companies say this eye drug offers advantages over Vabysmo, a Roche drug approved for wet age-related macular degeneration and diabetic…
-
STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC
WASHINGTON — The Food and Drug Administration is proposing a new classification for a product that’s existed in a legal gray area for years, a win for proponents of dietary supplements, including members of the MAHA movement. The proposed…
-
STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity
Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, which is sold as Wegovy by Novo Nordisk for combating obesity, started to become available in some countries and will soon arrive in still…
-
STAT+: NIAID acting head John Powers III appointed as the permanent director
The acting director of the National Institute of Allergy and Infectious Diseases, John Powers III, will become the permanent director, the agency announced Monday. NIAID has been without a permanent director since March 2025, when the…
-
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.
-
CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.
-
J&J bets $2.2B on Ollin’s vision loss drug
The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
-
STAT+: Biotech’s rebound isn’t lifting all boats equally
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. This Science story about how “neurons in a dish are the newest computing machines” dances with the plot line of the…
-
STAT+: Suing Joe the Plumber and Microsoft, and diminishing raises
This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here . Hello! Glad you’re here. FYI: Amazing tweets still exist . Don’t be shy, tell me what’s on your mind: bob.herman@statnews.com . The air ambulance…
-
The Permanente Medical Group Launches Innovation Company To Commercialize Clinicians’ Ideas
Kaiser Permanente’s physician organization, the largest physician-led medical group in the country, is launching a healthcare innovation company meant to help grow clinicians’ ideas into healthcare realities. The post The Permanente…
-
A Complete Medical Record Still Won’t Fix Prior Authorization
The chart may be complete, and two parties may still reach different conclusions. The issue is not always what they know; it is how the organization interprets what it knows. The post A Complete Medical Record Still Won’t Fix Prior…
-
Safety and Regulation Must Lead the Way in Healthcare AI Innovation
By applying proven and enforceable guardrails, coupled with smart financial incentives, we can ensure AI elevates medical care while maintaining the trust that holds our health system together. The post Safety and Regulation Must Lead the…
-
Ongoing Check-Ins Can Help More Postpartum Mothers Get the Care They Need
Engaging with mothers earlier gives us the best chance of catching PPD, PPA, and PPP before they escalate. It won’t be perfect, but it will help more moms and their families. The post Ongoing Check-Ins Can Help More Postpartum Mothers Get…
-
STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings, and phone calls has predictably returned. But what…
-
Democrats settle on a message: ‘Medicare for More’
Good morning and happy Monday! Today’s newsletter features some pretty saucy tidbits. We’ve got a doctor on why hot baths and “wellness modules” can’t cure the profession’s burn out, two medical school professors on why med school just…
-
STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
A psychedelic drug candidate from Helus Pharma significantly helped people with major depression in a Phase 3 trial, the company said Monday, but a number of serious adverse events in the study raised questions about the safety of the…
-
STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence
A cancer immunotherapy from CG Oncology delivered into the bladders of patients reduced the risk of tumor recurrence by 68% compared to current medical practice — positive study results announced Monday that may change the way physicians…
-
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
Lilly’s 15th announced acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.
-
ARPA-H Spotlights Innovative Health Tech and MedTech at INVEST Digital Health
[Sponsored] The Innovation Showcase at the Dallas conference included technology to objectively assess pain, as well as startups seeking to speed up diagnosis of endometriosis, improve the way we communicate and precision nutrition. The…
-
STAT+: Venture capitalist John Doerr says AI company, named for his late brother, could help fix primary care
When asked about Tom, a new company being announced, John Doerr, the legendary Kleiner Perkins venture capitalist, paused, seeming near tears, and requested a moment. The company is named after his brother. “I’m getting emotional because…
-
Big-name investors pour $100M into DNA therapeutics developer Seawolf
The startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm.
-
STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Versant Ventures, Eli Lilly, and a handful of other investors announced Monday that they have poured $100 million into a new startup devoted to solving a gene therapy challenge that has ensnared many well-funded academics and biotechs…
-
The infrastructure decisions that will enable tomorrow’s biggest breakthroughs
Faster drug discovery depends on more than the model. What drug developers need to know about AI.
-
Completing the circle: the next evolution in sustainable pharmaceutical blister packaging
Discover how innovative PET and PP lidding are advancing sustainable pharmaceutical blister packaging.
-
Your AI pilots aren’t stalling because of the AI – they’re stalling because of your environment
As clinical AI adoption accelerates, trust, traceability and readiness matter more than ever.
-
After difficult two years, medical school group’s leadership isn’t letting its guard down post midterms
ANAHEIM, Calif. — After spending a tumultuous two years entangled in many of the most consequential health and science policy debates of President Trump’s second term, the Association of American Medical Colleges isn’t ready to let its…
-
STAT+: With Stephen Miller as chief of staff, Kennedy’s MAHA agenda is reinvigorated
WASHINGTON — Even as Republicans pick up the pieces following devastating midterm election losses , spirits are high at the Department of Health and Human Services, where recent changes in the administration — namely the appointment of…
-
Opinion: STAT+: Candles and long baths can’t fix burned-out physicians
Welcome to Chief Complaint , a new STAT+ column from Frances Mei Hardin, M.D. A former ear, nose, and throat surgeon, she writes about the many challenges facing those who practice medicine in a time of great change. During my second year…
-
BeOne, Hengrui top list of China’s most powerful drugmakers
China’s ascendant drug industry is no monolith, despite how it’s often described by Western competitors, pundits, and policymakers. The country is home to scores of companies with diverging ambitions, founded last year or last century…
-
Opinion: Medical school should start after students take the Step 1 exam
This article is the first in a new First Opinion series on redesigning medical school. There are more than 150 medical schools across the United States, and although each has a unique approach to medical education, all must grapple with…
-
One of Europe’s leading VCs banks a €725M ‘crossover’ fund
Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.
-
MMAO: Mechanism and Stability Analysis of Metabolic Closed-Loop Metaheuristics
arXiv:2607.01551v3 Announce Type: replace Abstract: This paper studies the Metabolic Multi-Agent Optimizer (MMAO) at the framework level rather than at the implementation or benchmark level. The central question is whether the metabolic…
-
Ternary Spiking Neural Networks Enhanced by Complemented Neurons and Membrane Potential Aggregation
arXiv:2601.15598v2 Announce Type: replace Abstract: Spiking Neural Networks (SNNs) are promising energy-efficient models and powerful framworks of modeling neuron dynamics. However, existing binary spiking neurons exhibit limited…
-
TSGP-2: On the Non-Linearity of Symbolic Regression Problems and How to Exploit It with Model-based Semantic Genetic Programming
arXiv:2611.17455v1 Announce Type: new Abstract: Model-based variation operators such as the one used in Transformer Semantic Genetic Programming (TSGP) are affected by possible biases of their training data. TSGP is trained, in particular…
-
MMAO-Dyn: A Metabolic Multi-Agent Optimizer for Dynamic Optimization
arXiv:2607.00846v3 Announce Type: replace Abstract: This paper studies whether the Metabolic Multi-Agent Optimizer (MMAO) can be credibly derived into a dynamic-optimization method without replacing its core metabolic control loop by…
-
Minimal MMAO: A Resource-Closed-Loop Framework for Adaptive Metaheuristic Search
arXiv:2606.30450v3 Announce Type: replace Abstract: This paper presents the Metabolic Multi-Agent Optimizer (MMAO) as an adaptive metaheuristic built around endogenous resource circulation. The central premise is that search intensity…
-
Few-Shot Open-Set Hyperspectral Pixel-Wise Classification with Spatial Aware Label Propagation
arXiv:2611.17974v1 Announce Type: cross Abstract: Pixelwise classification of hyperspectral images (HSI) is a fundamental task in remote sensing, but its deployment in real-world applications is often limited by the scarcity of labeled…
-
MMAO: A Metabolic Multi-Agent Optimizer with Endogenous Resource Allocation for Continuous and Discrete Optimization
arXiv:2606.28109v3 Announce Type: replace Abstract: Traditional meta-heuristics often rely on fixed population sizes, manually chosen search scales, and externally attached parameter-control modules. This paper presents the Metabolic…
-
A Large-Scale Empirical Evaluation of MMAO Under Fair-Budget Continuous and Discrete Benchmarks
arXiv:2606.31584v3 Announce Type: replace Abstract: This paper evaluates the Metabolic Multi-Agent Optimizer (MMAO) under a stricter empirical protocol rather than reintroducing the framework itself. The study asks whether MMAO's…
-
Duet Secures $15M to Grow Network of Nurse Practitioner-Owned Clinics
Duet’s Series A round was led by Kairos, with participation from Lerer Hippeau. The post Duet Secures $15M to Grow Network of Nurse Practitioner-Owned Clinics appeared first on MedCity News .
-
STAT+: Apple and OpenEvidence launch experimental health chat app
LAS VEGAS — Apple and OpenEvidence on Sunday launched a study based around an experimental artificial intelligence-powered health chat application, hinting at possible new directions for both companies. Sumbul Desai, Apple’s vice president…
-
A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo
Nature Biotechnology, Published online: 16 November 2026; doi:10.1038/s41587-026-03344-5 Adeno-associated virus vectors targeted to CD7 enable T and NK cell engineering in vivo.